Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug targets tough cancers with KRAS G12D mutation

NCT ID NCT06586515

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 25, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug, LY3962673, in people with advanced solid tumors that have a specific KRAS G12D mutation, including pancreatic, lung, and colorectal cancers. The main goals are to check safety and see if the drug shrinks tumors, given alone or with chemotherapy. About 630 participants will be enrolled, and the study lasts around 5 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 630 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have Histological or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Have evidence of KRAS G12D mutation in tumor tissue or circulating tumor DNA * Have an ECOG performance status of ≤ 1 * Must have received ≥ 1 prior line of systemic chemotherapy for advanced or metastatic disease * Participants with asymptomatic or treated CNS disease may be eligible. Exclusion Criteria: * Have known active CNS metastases and/or carcinomatous meningitis. * Have any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 1. * Have significant cardiovascular disease as unstable angina or acute coronary syndrome, history of myocardial infarction, known reduced left ventricular ejection fraction. * Have active uncontrolled systemic bacterial, viral, fungal, or parasitic infection. * Have known active hepatitis B virus (HBV) and hepatitis C virus (HCV). * Have other active malignancy unless in remission with life expectancy greater than (\>) 2 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm non-small cell lung carcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer Non small cell lung cancer Pancreatic ductal adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    52 sites in 9 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aichi Cancer Center Hospital

    RECRUITING

    Nagoya, 464-8681, Japan

  • Azienda Ospedaliera Universitaria - Universita degli Studi della Campania Luigi Vanvitelli

    RECRUITING

    Naples, 80138, Italy

  • Barbara Ann Karmanos Cancer Institute

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Beijing Cancer hospital

    NOT_YET_RECRUITING

    Beijing, 100142, China

  • Cancer Institute & Hospital, Chinese Academy of Medical Sciences

    NOT_YET_RECRUITING

    Beijing, 100021, China

  • Centre Leon Berard

    NOT_YET_RECRUITING

    Lyon, 69373, France

  • Centre d'Essais Precoces en Cancerologie de Marseille (CEPCM) - AP-HM Hopital de La Timone

    NOT_YET_RECRUITING

    Marseille, 13005, France

  • Centro Ricerche Cliniche di Verona s.r.l.

    RECRUITING

    Verona, 37134, Italy

  • Charite Universitaetsmedizin Berlin

    RECRUITING

    Berlin, 10117, Germany

  • City of Hope

    RECRUITING

    Duarte, California, 91010, United States

  • Cleveland Clinic

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Community Health Network

    RECRUITING

    Indianapolis, Indiana, 46250, United States

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • Duke University Medical Center

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Emory University School of Medicine

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute

    RECRUITING

    Orlando, Florida, 32827, United States

  • Fred Hutchinson Cancer Center

    RECRUITING

    Seattle, Washington, 98109, United States

  • Fudan University Shanghai Cancer Center

    NOT_YET_RECRUITING

    Shanghai, 200032, China

  • Harbin Medical University Cancer Hospital

    NOT_YET_RECRUITING

    Harbin, 150081, China

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitario Vall d'Hebron

    RECRUITING

    Barcelona, 08035, Spain

  • Huntsman Cancer Institute

    RECRUITING

    Salt Lake City, Utah, 84112, United States

  • Institut Gustave Roussy

    NOT_YET_RECRUITING

    Villejuif, 94805, France

  • Kanagawa cancer center

    RECRUITING

    Kanagawa, 241-8515, Japan

  • Kansai Medical University Hospital

    RECRUITING

    Osaka, 573-1191, Japan

  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen

    RECRUITING

    München, 81377, Germany

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02114, United States

  • National Cancer Center Hospital

    RECRUITING

    Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    RECRUITING

    Chiba, 277-8577, Japan

  • New York University (NYU) Langone Medical Center

    RECRUITING

    New York, New York, 10016, United States

  • Oncopole Claudius Regaud

    NOT_YET_RECRUITING

    Toulouse, 31059, France

  • Princess Margaret Hospital

    RECRUITING

    Toronto, M5G 2M9, Canada

  • START Dublin Early Phase Clinical Trials Unit

    RECRUITING

    Dublin, D07 R2WY, Ireland

  • Sarah Cannon Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Sarah Cannon Research Institute at HealthOne

    RECRUITING

    Denver, Colorado, 80218, United States

  • Sibley Memorial Hospital

    RECRUITING

    Washington D.C., District of Columbia, 20016, United States

  • South Texas Accelerated Research Therapeutics (START)

    RECRUITING

    San Antonio, Texas, 78229, United States

  • South Texas Accelerated Research Therapeutics (START) Barcelona- HM Nou Delfos

    RECRUITING

    Barcelona, 08023, Spain

  • South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz

    RECRUITING

    Madrid, 28040, Spain

  • South Texas Accelerated Research Therapeutics (START) Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • The Ottawa Hospital

    RECRUITING

    Ottawa, K1H 8L6, Canada

  • UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

    RECRUITING

    Roma, 00168, Italy

  • USO - US Oncology Research Network

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Universitaetsklinikum Carl Gustav Carus Dresden

    RECRUITING

    Dresden, 01307, Germany

  • Universitaetsklinikum Essen

    RECRUITING

    Essen, 45147, Germany

  • University of California, Los Angeles (UCLA)

    RECRUITING

    Santa Monica, California, 90404, United States

  • University of Cincinnati (UC) - Cancer Institute

    RECRUITING

    Cincinnati, Ohio, 45267, United States

  • University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Wisconsin - Carbone Cancer Center

    RECRUITING

    Madison, Wisconsin, 53792, United States

  • Vanderbilt University School of Medicine

    RECRUITING

    Nashville, Tennessee, 37215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.